REDWOOD CITY, Calif., Nov. 20, 2018 /PRNewswire/ -- Synthego, the leading provider of genome engineering products, and Eurofins Genomics, a global leader in bioanalytical testing, announced a groundbreaking partnership today. Through this agreement, Eurofins will distribute Synthego's synthetic single guide RNA (sgRNA) to their global customer database across 44 countries.
CRISPR technology is being adopted by labs worldwide. However, researchers still spend a considerable amount of time and effort achieving the desired editing efficiencies in their CRISPR experiments. Synthego aims to minimize the optimization time through their revolutionary CRISPR product portfolio, thus allowing genome engineers to focus on their research. Synthego's industry-best, chemically modified and unmodified sgRNAs deliver unparalleled editing efficiencies of up to 97%, allowing superior editing in virtually any cell type.
Eurofins Genomics is part of the Eurofins Scientific Group (SE), the world leader in food, pharma and environmental laboratory testing, as well as a market leader in agroscience, genomics and product testing services. Eurofins Genomics is known globally for its innovative technologies in the life sciences arena including academic institutions, biotech companies and the pharmaceutical industry.
Eurofins Genomics and Synthego are ideal business partners given their unmatched flexibility for any kind of genomic research and applications of CRISPR. A combined understanding of their customers' challenges with CRISPR was the basis for the cooperation between the two life sciences leaders, and aligned interests and values in offering best in class solutions make the Eurofins-Synthego partnership all the more powerful.
Ted Tisch, Chief Operating Officer of Synthego: "CRISPR and genome engineering has the potential to address some of society's biggest challenges, but more scientists need access to products that can accelerate their research. The cooperation with Eurofins Genomics offers an expert network and a reliable, wide distribution organization. Synthego's synthetic RNA products have proven to be predictable, scalable and efficient in helping customers capture this potential."
Currently, eight of the 10 largest global biotechnology companies and 24 of the top 25 global biology universities around the world use Synthego's high-quality sgRNAs, but the company's mission is to enable easy CRISPR access to all researchers worldwide. Partnering with Eurofins bolsters Synthego's market reach across the globe, and is a huge step toward increasing wide access to its capabilities.
Dr. Michael Hadem, CEO Eurofins Genomics Europe: "Synthetic RNAs from Synthego enable our customers to perform better research faster and more accurately. The cooperation with Synthego in the CRISPR field is the perfect addition to our comprehensive genomics product portfolio."
Synthetic guide RNA products available under the Eurofins Scientific brand include synthetic crRNA:tracrRNA, synthetic single guide RNA (sgRNA), and chemically modified synthetic sgRNA.
Synthego is the genome engineering innovation company. The company's automated, full-stack genome engineering platform enables broader access to CRISPR to accelerate basic scientific discovery, uncover critical disease cures and develop novel synthetic biology applications to solve some of society's biggest challenges. Headquartered in Silicon Valley, Synthego is used by scientists from the largest global biotechnology companies and global biology universities to unlock the potential of gene editing.
Eurofins Scientific through its subsidiaries (hereinafter sometimes "Eurofins" or "the Group") believes it is a scientific leader in food, environment and pharmaceutical products testing and in agroscience CRO services. It is also one of the independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and for supporting clinical studies. In addition, Eurofins is one of the emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 40,000 staff in more than 650 laboratories across 45 countries, Eurofins offers a portfolio of over 150,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Bateman Group for Synthego PR